Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers

(2021) Nisha B. Nagarsheth et al.   NATURE MEDICINE

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

(2020) Jennifer N. Brudno et al.   NATURE MEDICINE

Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function

(2020) Frederike A. Hartl et al.   NATURE IMMUNOLOGY

Inefficient CAR-proximal signaling blunts antigen sensitivity

(2020) Venugopal Gudipati et al.   NATURE IMMUNOLOGY

Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic

(2019) Laura T. Morton et al.   MOLECULAR THERAPY

Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function

(2019) Sharyn Thomas et al.   Nature Communications

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity

(2018) A. J. Davenport et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Strategies to Address Chimeric Antigen Receptor Tonic Signaling

(2018) Adam Ajina et al.   MOLECULAR CANCER THERAPEUTICS

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

(2018) Judith Feucht et al.   NATURE MEDICINE

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains

(2017) Daniel T. Harris et al.   JOURNAL OF IMMUNOLOGY

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

Therapeutic T cell engineering

(2017) Michel Sadelain et al.   NATURE

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent

(2017) Diogo Gomes-Silva et al.   Cell Reports

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

(2016) Omkar U. Kawalekar et al.   IMMUNITY

Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies

(2016) Lorenz Jahn et al.   Oncotarget

Toxicity and management in CAR T-cell therapy

(2016) Challice L Bonifant et al.   Molecular Therapy-Oncolytics

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy

(2016) Vita Golubovskaya et al.   Cancers

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(2015) Aaron P Rapoport et al.   NATURE MEDICINE

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Generation of knock-in primary human T cells using Cas9 ribonucleoproteins

(2015) Kathrin Schumann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD

(2015) A. Kunkele et al.   Cancer Immunology Research

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treating cancer with genetically engineered T cells

(2011) Tristen S. Park et al.   TRENDS IN BIOTECHNOLOGY

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

T-cell receptor gene transfer for the treatment of leukemia and other tumors

(2010) M. H.M. Heemskerk   HAEMATOLOGICA

Long–term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors

(2009) Bart A. Nijmeijer et al.   EXPERIMENTAL HEMATOLOGY